Mononuclear Therapeutics Ltd. Report issue

For profit Phase 1
Founded: Hong Kong Hong Kong (2015)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2018
NCT03352310
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Mononuclear Therapeutics Ltd.

Active Ingredients

Drugs in Phase 1 Trials (1)

autologous umbilical cord blood (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 1)

Anemia, Neonatal (Phase 1)

Brain Diseases (Phase 1)

Brain Ischemia (Phase 1)

Cerebral Infarction (Phase 1)

Hypoxia (Phase 1)

Hypoxia-Ischemia, Brain (Phase 1)

Ischemia (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1